ILMN stock performance?

Illumina, Inc. (ILMN) news stock charts

Illumina, Inc. (ILMN) Investment Summary:

This Annual Report on Form 10-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Item 1A.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f26%2f0000936392-08-000144.html#FIS_BUSINESS"   
www.illumina.com
1,781 Employees
Founded in 1998

ILLUMINA INC (ILMN:NASDAQ)

LAST $39.85 USD
CHANGE TODAY +0.20 0.50%
VOLUME 1.1M
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of ILLUMINA INC (ILMN)

OPEN
$39.75
PREVIOUS CLOSE
$39.65
DAY HIGH
$40.12
DAY LOW
$39.63
52 WEEK HIGH
10/6/09 - $44.07
52 WEEK LOW
11/23/09 - $25.59
MARKET CAP
4.8B
AVERAGE VOLUME 10 D
1.3M
EPS TTM
$0.65
SHARES OUTSTANDING
120.3M
ILMN Does Not Pay Dividends
P/E TTM
61.3x
K = Thousands  M = Millions  B = Billions

related news

Life Science Stocks: A Growing Market in 2010
12/27/2009 11:18 PM ET
Stocks Tumble on Jobs News
07/02/2009 4:40 PM ET
Stocks Tumble on Jobs News
07/02/2009 4:40 AM ET
The Weird World of ETFs
02/08/2007 12:00 AM ET

related news

Merger isn't cramping Life Technologies' style [The San Diego Union-Tribune]
The McClatchy Company - 03/21/2010 10:12 AM ET

Key developments for ILLUMINA INC (ILMN)

Illumina Announces HumanOmniExpress+ Custom BeadChip
03/16/2010

Illumina Inc. unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry's most optimal set of SNPs. The HumanOmniExpress+ Custom BeadChip is the most versatile custom genotyping product available, with industry-standard data quality ensured by the robust Infinium assay, flexible content design, and high throughput capabilities supported by a multisample BeadChip. Similar to researchers currently using iSelect, OmniExpress+ users will have access to Illumina's assay design software for seamless content design, ensuring the best assay success rate in the industry without the need to pre-screen. Together with the iScan System and an 8-sample array format, the OmniExpress+ enables the processing of more than 900 samples per week. Like OmniExpress, the foundation of the markers on the OmniExpress+ is a subset of the content powering Illumina's flagship GWAS product, the HumanOmni1-Quad, and includes an optimized set of SNPs chosen from all three phases of the International HapMap Project. Researchers starting with OmniExpress+ can take advantage of future supplemental Omni BeadChips containing new content derived from the 1,000 Genomes Project. As with all Infinium HD products, the OmniExpress BeadChip supports copy number variation analyses for disease-association studies and is compatible with Illumina's automation solutions.

Illumina Inc. Announces Resignation of Joel McComb as Senior Vice President & General Manager, Life Sciences Effective Feb. 28, 2010
02/23/2010

Illumina Inc. announced that Joel McComb resigned from his position as Senior Vice President & General Manager, Life Sciences of the company to pursue other professional opportunities. Mr. McComb's resignation will be effective February 28, 2010.

Illumina Inc. Presents at BayBio2010, Apr-07-2010
02/12/2010

Illumina Inc. Presents at BayBio2010, Apr-07-2010. Venue: Hyatt Regency San Francisco Airport, 1333 Bayshore Highway, Burlingame, California, United States. Speakers: Omead Ostadan, Vice President.

Illumina, Inc. financial resources

otc, otcbb, pinksheet, ILMN, ob Illumina, Inc.

ILMN Competitors

Company Last Change
Gen-Probe Inc $47.44 USD +0.49
Hologic Inc $18.67 USD -0.89
QIAGEN NV €17.00 EUR +0.11
Varian Inc $51.76 USD -0.02
Waters Corp $65.06 USD -0.95
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation ILMN Industry Range
Price/Earnings 75.6x
Price/Sales 7.3x
Price/Book 5.5x
Price/Cash Flow 60.7x
TEV/Sales 5.7x

ILMN
 | 

ILMN transactions

Type
Date		 Target
Buyback
November 25, 2009 		--

More Recent Financial News About Illumina, Inc.

ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers

2010-02-24 08:46:29
Quote: Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 22, 2010, Joel McComb resigned from his position as Senior Vice President & General Manager, Life Sciences of Illumina, Inc. (the "Company") to pursue other professional opportunities. Mr. McComb's resignation will be effective February 28, 2010. In connection with his resignation, Mr. McComb and the Company ente...
Read article

Q4 2009 Illumina, Inc. Earnings Release - After Market Close

2010-02-05 02:36:49
Quote: Gregg Appliances IncHGG0.45Time Not SuppliedAddHarman International IndustriesHAR0.07Time Not SuppliedAddHarmonicHLIT0.05After Market CloseAddListenHawaiian Holdings, Inc.HA0.12After Market CloseAddListenHexagon ABHXGBF.PKN/A02:00 am ETAddHILLENBRAND INCHI0.4Before Market OpenAddHitachi LimitedHITN/A01:00 am ETAddHospiraHSP0.69Before Market OpenAddListenHULIC CO LTD, TOKYOHULIF.PKN/ATime Not SuppliedAddHUNAN HUATIAN GREAT HOTEL CO000428.SZN/ATime Not SuppliedAddIllumina, Inc.ILMN0.19After Market...
Read article

ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition

2010-02-05 02:36:46
Quote: Item 2.02 Results of Operations and Financial Condition. On February 4, 2010, Illumina, Inc. issued a press release announcing financial results for the fourth quarter and year ended January 3, 2010. The full text of the company's press release is attached hereto as Exhibit 99.1. This Form 8-K, including the exhibit hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as "f...
Read article

Illumina, Inc Q4 2009 Earnings Call Transcript

2010-02-05 02:36:45
Quote: Illumina, Inc (ILMN) Q4 2009 Earnings Call February 4, 2010 5:00 pm ET Executives Jay Flatley - President and CEO Christian Henry - SVP of Corporate Development and CFO Peter Fromen - Senior Director of IR Analysts Ross Muken - Deutsche Bank Tycho Peterson - JPMorgan Marshall Urist - Morgan Stanley Doug Schenkel - Cowen and Company Bill Quirk - Piper Jaffray Jon Groberg - Macquarie Madden - Robert W. Bair Dan Arias - UBS Isaac Ro - Leerink Swann May-Kin Ho - Goldman Sachs Dan Leonard - First Ana...
Read article

Gene Machine Wars Get Ever Hotter

2010-01-29 01:36:53
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Just weeks after Illumina, the leader in the DNA sequencing market, announced a new machine that could sequence a human genome for $10,000 in materials, competitor Life Technologies announced its own new gene sequencer that could do the job for $6,000. The company is also setting aside money to train physicians in using genetic information. Life shares rose 2% in morning trading. But although the news is good for Life and will keep it in the game as the price of decoding the genetic code continu...
Read article

Genomic Testing Systems Create Sustainable Competitive Advantage For Selected Medical Diagnostic Stocks According To Award Winning Equity Analyst

2010-01-26 04:34:42
Quote: Ro: Genomics is really led by a good margin at this point by Illumina, ILMN. I just raised my price target for them because I believe this company is innovating not only in genomics, but they actually also have an entree eventually into the diagnostics world as well. So there are a couple of things that, over the next couple of years, that are going to change the market and could take them well over $1 billion in revenues. TWST: What exactly will change the market? Mr. Ro: The first product is t...
Read article

Illumina, Inc. Earnings Call scheduled for Thu, Feb 4

2010-01-22 03:28:06
Quote: Call DetailsIllumina, Inc. Earnings Conference Call (Q4 2009)Scheduled to start Thu, Feb 4, 2010, 5:00 pm EasternAfter the event has finished, the audio will be availablefrom this page until Sat, Feb 5, 2011About Illumina, Inc.ILMN)Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include Genome Analyzer II, an instrument for high-throughput sequencing using Illum...
Read article

Illumina Announces Preliminary Revenue for Fourth Quarter 2009

2010-01-13 02:16:14
Quote: Our tools provide researchers around the worldwith the performance, throughput, cost effectiveness, and flexibilitynecessary to perform the billions of genetic tests needed to extractvaluable medical information from advances in genomics and proteomics.We believe this information will enable researchers to correlate geneticvariation and biological function, which will enhance drug discovery andclinical research, allow diseases to be detected earlier, and permitbetter choices of drugs for individ...
Read article

Illumina Preliminary Revenue Beats Forecast; Company Announces New Tech

2010-01-13 02:16:11
Keywords: Illumina Preliminary Revenue Beats Forecast; Company Announces New Tech, Genome sequencing
Quote: Illumina, Inc. (ILMN) shares rose inTuesday’s trading session after the genetic researching firm’s Chief Executive Jay Flatley announced at the JPMorgan HealthCare Conference that it has developed technology that can sequence the entire genetic code for a person for under $10,000,according to The Wall Street Journal.The Journal reported that the current cost for genetic code sequencing is around $50,000.Illumina also announced preliminary revenue, Tuesday for the fiscal fourth quar...
Read article

Would you like to leave a comment about Illumina, Inc. ILMN

Find out what social network information about Illumina, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Illumina, Inc.'s Stock there is more great penny stock and market information at Realpennies